Abstract：
UNASSIGNED: The aim of this study was to investigate the clinical use of sodium hyaluronate (SH) combined with pranoprofen in treating patients with dry eye.
UNASSIGNED: A total of 117 patients with dry eye who were treated in the Traditional Chinese Medicine Hospital of Kunshan from March 2020 and May 2022 were included. According to the therapy approaches, they were treated with SH (SH group), pranoprofen (pranoprofen group), and SH combined with pranoprofen (joint group) (n = 39).
UNASSIGNED: The effective rates of dry eye were 79.49%, 74.36% and 94.87% in the SH group, the pranoprofen group and the joint group, respectively (p < 0.05). After treatment, the tear BUT and SIT in the joint group were all prominently increased than those in the other two groups (p < 0.05). The corneal fluorescein staining and dry eye symptom scores in the joint group after treatment were dramatically lower than those in the other two groups (p < 0.001). After treatment, the visual contrast sensitivity (12 c/d, 18 c/d and 24 c/d) in the joint group was markedly higher than those in the other two groups (p < 0.001). The CPR, TNF-α, IFN-γ and IL-1β levels in the joint group were notably decreased than those in other two groups (p < 0.001). After treatment, the VRQOL quality-of-life scores in the joint group were significantly higher than those in the other two groups (p < 0.05).
UNASSIGNED: SH combined with pranoprofen showed clear therapeutic benefit in treating dry eye, and the curative effect was more favorable than with either medication alone.
UNASSIGNED: A total of 117 patients with dry eye who were treated in the Traditional Chinese Medicine Hospital of Kunshan from March 2020 and May 2022 were included. According to the therapy approaches, they were treated with SH (SH group), pranoprofen (pranoprofen group), and SH combined with pranoprofen (joint group) (n = 39).
UNASSIGNED: The effective rates of dry eye were 79.49%, 74.36% and 94.87% in the SH group, the pranoprofen group and the joint group, respectively (p < 0.05). After treatment, the tear BUT and SIT in the joint group were all prominently increased than those in the other two groups (p < 0.05). The corneal fluorescein staining and dry eye symptom scores in the joint group after treatment were dramatically lower than those in the other two groups (p < 0.001). After treatment, the visual contrast sensitivity (12 c/d, 18 c/d and 24 c/d) in the joint group was markedly higher than those in the other two groups (p < 0.001). The CPR, TNF-α, IFN-γ and IL-1β levels in the joint group were notably decreased than those in other two groups (p < 0.001). After treatment, the VRQOL quality-of-life scores in the joint group were significantly higher than those in the other two groups (p < 0.05).
UNASSIGNED: SH combined with pranoprofen showed clear therapeutic benefit in treating dry eye, and the curative effect was more favorable than with either medication alone.
摘要：
■这项研究的目的是研究透明质酸钠（SH）联合普拉洛芬治疗干眼症患者的临床应用。
■纳入了2020年3月至2022年5月在昆山市中医医院治疗的117例干眼症患者。根据治疗方法，他们用SH治疗（SH组），普拉洛芬（普拉洛芬组），SH联合普拉洛芬（联合组）（n=39）。
■干眼的有效率为79.49%，SH组74.36%和94.87%,普拉洛芬组和联合组，分别为(p<0.05)。治疗后,联合组的泪液BUT和SIT均明显高于其他两组（p<0.05）。联合组治疗后角膜荧光素染色和干眼症状评分明显低于其他两组(p<0.001)。治疗后,视觉对比敏感度(12c/d，联合组18c/d和24c/d）明显高于其他两组（p<0.001）。CPR,TNF-α,联合组的IFN-γ和IL-1β水平明显低于其他两组（p<0.001）。治疗后,联合组的VRQOL生活质量评分明显高于其他两组（p<0.05）。
■SH联合普拉洛芬在治疗干眼方面显示出明显的治疗益处，疗效优于单独使用任何一种药物。
■纳入了2020年3月至2022年5月在昆山市中医医院治疗的117例干眼症患者。根据治疗方法，他们用SH治疗（SH组），普拉洛芬（普拉洛芬组），SH联合普拉洛芬（联合组）（n=39）。
■干眼的有效率为79.49%，SH组74.36%和94.87%,普拉洛芬组和联合组，分别为(p<0.05)。治疗后,联合组的泪液BUT和SIT均明显高于其他两组（p<0.05）。联合组治疗后角膜荧光素染色和干眼症状评分明显低于其他两组(p<0.001)。治疗后,视觉对比敏感度(12c/d，联合组18c/d和24c/d）明显高于其他两组（p<0.001）。CPR,TNF-α,联合组的IFN-γ和IL-1β水平明显低于其他两组（p<0.001）。治疗后,联合组的VRQOL生活质量评分明显高于其他两组（p<0.05）。
■SH联合普拉洛芬在治疗干眼方面显示出明显的治疗益处，疗效优于单独使用任何一种药物。
